Under the agreement, PolyPeptide will manufacture f Scancell's first Moditope development candidate Modi-1 Amplivant conjugate under the Good Manufacturing Practice standard.
The Moditope platform works by stimulating the production of CD4+ T cells, white blood cells that fights infection by using tumour-associated peptide epitopes, therefore overcoming the immune suppression caused by tumours themselves.
Scancell plans to conduct a phase 1/2 clinical trial of Modi-1 Amplivant in the first half of 2019 in patients with triple negative breast cancer, ovarian cancer and sarcomas.
"We are delighted to sign a deal with The PolyPeptide Group to manufacture our Modi-1 vaccine. Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019," said Chief Executive Officer Cliff Holloway.
Shares in Scancell Holdings were up 7.3% at
Scancell Holdings (SCLP)